Primary hepatic lymphoma

Ray D. Page(The University of Texas MD Anderson Cancer Center), Fernando Cabanillas(University of Puerto Rico, Medical Sciences Campus), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), José Rodríguez(The University of Texas MD Anderson Cancer Center), Barbara M. Osborne(The University of Texas MD Anderson Cancer Center), L. Jeffrey Medeiros(Delaware Division of Libraries), L North(The University of Texas MD Anderson Cancer Center), César Sanz-Rodrı́guez(Merck Biopharma Co., Ltd. (Japan))
Cancer
January 1, 2001
10.1002/1097-0142(20011015)92:8<2023::aid-cncr1540>3.0.co;2-b
Cited by 157

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|Journal of Clinical Oncology|2015|418
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|390
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience
|British Journal of Haematology|2014|364
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
|The Lancet Oncology|2014|263